Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Prostanoid EP1 receptor, also known as Prostaglandin E2 receptor 1 (EP1), is a G protein-coupled receptor (GPCR) that primarily binds prostaglandin E2 (PGE2). Activation leads to stimulation of phospholipase C (PLC), resulting in increased intracellular inositol trisphosphate (IP3) and diacylglycerol (DAG), which mobilizes intracellular calcium (Ca2+). It mediates various physiological functions, including smooth muscle contraction and has been implicated in neurodegenerative diseases and cancer. Antagonists have shown efficacy in preclinical models for reducing neurotoxicity.
Gq protein activation, phospholipase C (PLC) stimulation, increased intracellular inositol trisphosphate (IP3) and diacylglycerol (DAG), mobilization of intracellular calcium (Ca2+)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostanoid EP1 Receptor (EP1).